MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis

This article discusses current literature on the use of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in the treatment of posttraumatic stress disorder (PTSD). MDMA, the intended active ingredient in illicit Ecstasy or Molly products, is a psychedelic that causes an elevated mood,...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical pharmacology Vol. 62; no. 4; p. 463
Main Authors Smith, Kimberly W, Sicignano, Dakota J, Hernandez, Adrian V, White, C Michael
Format Journal Article
LanguageEnglish
Published England 01.04.2022
Subjects
Online AccessGet more information

Cover

Loading…
Abstract This article discusses current literature on the use of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in the treatment of posttraumatic stress disorder (PTSD). MDMA, the intended active ingredient in illicit Ecstasy or Molly products, is a psychedelic that causes an elevated mood, feeling of bonding, and increased energy. In MDMA-assisted psychotherapy, patients are subjected to 2 or 3 multihour sessions of therapy with a team of psychiatrists. The dosing of MDMA is used to allow the therapist to probe the underlying trauma without causing emotional distress. The use of MDMA-assisted psychotherapy treatment reduced patient's Clinician-Administered PTSD Scale (CAPS) scores from baseline more than control psychotherapy (-22.03; 95%CI, -38.53 to -5.52) but with high statistical heterogeneity. MDMA-assisted psychotherapy enhanced the achievement of clinically significant reductions in CAPS scores (relative risk, 3.65; 95%CI, 2.39-5.57) and CAPS score reductions sufficient to no longer meet the definition of PTSD (relative risk, 2.10; 95%CI, 1.37-3.21) with no detected statistical heterogeneity. While therapy was generally safe and well tolerated, bruxism, anxiety, jitteriness, headache, and nausea are commonly reported. While MDMA-assisted psychotherapy has been shown to be an effective therapy for patients with PTSD with a reasonable safety profile, use of unregulated MDMA or use in the absence of a strongly controlled psychotherapeutic environment has considerable risks.
AbstractList This article discusses current literature on the use of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in the treatment of posttraumatic stress disorder (PTSD). MDMA, the intended active ingredient in illicit Ecstasy or Molly products, is a psychedelic that causes an elevated mood, feeling of bonding, and increased energy. In MDMA-assisted psychotherapy, patients are subjected to 2 or 3 multihour sessions of therapy with a team of psychiatrists. The dosing of MDMA is used to allow the therapist to probe the underlying trauma without causing emotional distress. The use of MDMA-assisted psychotherapy treatment reduced patient's Clinician-Administered PTSD Scale (CAPS) scores from baseline more than control psychotherapy (-22.03; 95%CI, -38.53 to -5.52) but with high statistical heterogeneity. MDMA-assisted psychotherapy enhanced the achievement of clinically significant reductions in CAPS scores (relative risk, 3.65; 95%CI, 2.39-5.57) and CAPS score reductions sufficient to no longer meet the definition of PTSD (relative risk, 2.10; 95%CI, 1.37-3.21) with no detected statistical heterogeneity. While therapy was generally safe and well tolerated, bruxism, anxiety, jitteriness, headache, and nausea are commonly reported. While MDMA-assisted psychotherapy has been shown to be an effective therapy for patients with PTSD with a reasonable safety profile, use of unregulated MDMA or use in the absence of a strongly controlled psychotherapeutic environment has considerable risks.
Author Hernandez, Adrian V
Sicignano, Dakota J
Smith, Kimberly W
White, C Michael
Author_xml – sequence: 1
  givenname: Kimberly W
  surname: Smith
  fullname: Smith, Kimberly W
  organization: University of Connecticut School of Pharmacy, Storrs, Connecticut, USA
– sequence: 2
  givenname: Dakota J
  surname: Sicignano
  fullname: Sicignano, Dakota J
  organization: University of Connecticut School of Pharmacy, Storrs, Connecticut, USA
– sequence: 3
  givenname: Adrian V
  orcidid: 0000-0002-9999-4003
  surname: Hernandez
  fullname: Hernandez, Adrian V
  organization: Unidad de Revisiones Sistemáticas y Meta-análisis (URSIGET), Vicerrectorado de Investigación, Universidad San Ignacio de Loyola (USIL), Lima, Peru
– sequence: 4
  givenname: C Michael
  orcidid: 0000-0002-9367-4893
  surname: White
  fullname: White, C Michael
  organization: Research Administration, Hartford Hospital, Hartford, Connecticut, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34708874$$D View this record in MEDLINE/PubMed
BookMark eNo1j1tLwzAcxYMo7qIPfgHJF-hM0lxa38rmDVYcbuLjSJt_aMd6IcmUfnsL06dz4MDv8Juhy7ZrAaE7ShaUEPZwKPtqQdNUXKApFYJFXBI-QTPvD4RQyQW9RpOYK5Ikik-Ry1d5FmXe1z6AwRs_lFUXKnC6H7DtHN450KGBNuDO4k3nQ3D61OhQl3gbHHiPV7XvnAH3iDO8HUbMef2A7xp-8FcdKpxD0FHW6uMw_tygK6uPHm7_co4-n592y9do_f7ytszWURmLWETUEEULoyEubUJMoQzlyoqYawkiHQVtqi2TMiVMFhS4pBogHpsqVCEYZ3N0f-b2p6IBs-9d3Wg37P_l2S8GIlxn
CitedBy_id crossref_primary_10_1089_derm_2023_0292
crossref_primary_10_3917_heg_131_0002
crossref_primary_10_3389_fpsyt_2024_1411234
crossref_primary_10_1007_s00213_024_06685_8
crossref_primary_10_1177_00048674231203898
crossref_primary_10_1177_08901171231210806e
crossref_primary_10_1001_jamapsychiatry_2024_3532
crossref_primary_10_7759_cureus_44905
crossref_primary_10_1080_02791072_2024_2401977
crossref_primary_10_1177_00048674241240597
crossref_primary_10_3389_fpsyt_2022_983285
crossref_primary_10_1177_10600280231199666
crossref_primary_10_1016_j_neulet_2022_136710
crossref_primary_10_1080_02791072_2023_2272832
crossref_primary_10_1038_s41386_023_01656_7
crossref_primary_10_1055_a_2283_0238
crossref_primary_10_1038_s41386_024_01865_8
crossref_primary_10_1016_j_neuropharm_2023_109418
crossref_primary_10_3389_fpsyg_2025_1528253
crossref_primary_10_1007_s11920_024_01577_2
crossref_primary_10_1177_08901171231210806
crossref_primary_10_1038_s41598_023_40856_5
crossref_primary_10_3389_fpubh_2023_1274719
crossref_primary_10_1038_s41598_023_41199_x
crossref_primary_10_1080_09540261_2024_2357668
crossref_primary_10_1055_a_2453_0910
crossref_primary_10_1080_02791072_2025_2474246
crossref_primary_10_1177_02537176241294146
crossref_primary_10_1021_acsmedchemlett_2c00389
crossref_primary_10_1038_s41591_023_02705_w
crossref_primary_10_7759_cureus_57049
crossref_primary_10_1089_jpm_2022_0036
crossref_primary_10_1016_j_nbd_2023_106348
crossref_primary_10_1176_appi_ajp_20230902
crossref_primary_10_1177_02698811241265762
crossref_primary_10_2174_1570159X21666230428091433
crossref_primary_10_1089_lgbt_2024_0103
crossref_primary_10_36303_SAGP_2022_3_2_0123
crossref_primary_10_1080_02791072_2023_2274382
crossref_primary_10_1002_fhu2_70009
crossref_primary_10_3389_fpsyt_2022_991753
crossref_primary_10_1097_COC_0000000000000998
crossref_primary_10_1126_sciadv_adl6554
crossref_primary_10_1007_s11910_024_01353_y
crossref_primary_10_1016_j_psychres_2022_115020
crossref_primary_10_1080_20008066_2024_2366049
crossref_primary_10_1002_npr2_12485
crossref_primary_10_1016_j_nurpra_2023_104586
crossref_primary_10_1016_j_scitotenv_2024_176906
crossref_primary_10_1038_s41380_024_02800_5
crossref_primary_10_5664_jcsm_10074
crossref_primary_10_3390_molecules27092977
crossref_primary_10_1055_a_2282_4731
crossref_primary_10_1177_10600280221144055
crossref_primary_10_1080_13576275_2024_2434456
crossref_primary_10_1007_s00278_024_00715_8
crossref_primary_10_1016_j_ajp_2024_104193
crossref_primary_10_1186_s12909_024_06141_3
crossref_primary_10_3390_jcm11123255
crossref_primary_10_1007_s11920_023_01446_4
crossref_primary_10_3389_fpsyg_2022_866018
crossref_primary_10_1002_jppr_1921
crossref_primary_10_1016_j_psc_2024_04_012
crossref_primary_10_1016_j_euroneuro_2023_05_008
crossref_primary_10_1007_s00213_024_06593_x
ContentType Journal Article
Copyright 2021, The American College of Clinical Pharmacology.
Copyright_xml – notice: 2021, The American College of Clinical Pharmacology.
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1002/jcph.1995
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1552-4604
ExternalDocumentID 34708874
Genre Meta-Analysis
Systematic Review
Journal Article
GroupedDBID ---
.55
.GJ
05W
0R~
123
18M
1CY
1OB
1OC
29K
33P
34G
39C
3O-
3SF
4.4
52U
52V
53G
5RE
8-1
AAESR
AAEVG
AAHQN
AAIPD
AAMMB
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAWTL
AAXRX
AAYCA
AAZKR
ABCUV
ABJNI
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCZN
ACGFO
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACRPL
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADMGS
ADNMO
ADOZA
ADSTG
ADXAS
AEFGJ
AEGXH
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFFNX
AFFPM
AFGKR
AFRAH
AFWVQ
AGHNM
AGQPQ
AGXDD
AGYGG
AHBTC
AHMBA
AI.
AIACR
AIAGR
AIDQK
AIDYY
AITYG
AIURR
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AUVAJ
AVWKF
AZFZN
AZVAB
BDRZF
BFHJK
BHBCM
BMXJE
BOGZA
BRXPI
C45
CAG
CGR
COF
CS3
CUY
CVF
D-I
DCZOG
DPXWK
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
ECM
EIF
EJD
EMOBN
F5P
FEDTE
FUBAC
G-S
GODZA
GWYGA
H13
HF~
HGLYW
HVGLF
IAO
IEA
IHR
INH
INR
IVC
KBYEO
LATKE
LEEKS
LH4
LOXES
LSO
LUTES
LW6
LYRES
MEWTI
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
MY~
N9A
NPM
O66
O9-
OVD
P2P
P2W
PALCI
PQQKQ
R.K
RIWAO
RJQFR
ROL
SAMSI
SUPJJ
SV3
TEORI
VH1
WBKPD
WH7
WIH
WIJ
WIK
WOHZO
WOIKV
WPGGZ
WXSBR
X7M
ZGI
ZXP
ZZTAW
ID FETCH-LOGICAL-c3535-1d071bdae3cf80db7d147f534a6e59995f9af2669026b1e461aee3b1e7b7b5242
IngestDate Mon Jul 21 06:06:23 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords drug development
clinical pharmacology
CPH
drug abuse
psychiatry (PSY)
psychopharmacology (PSP)
Language English
License 2021, The American College of Clinical Pharmacology.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c3535-1d071bdae3cf80db7d147f534a6e59995f9af2669026b1e461aee3b1e7b7b5242
ORCID 0000-0002-9367-4893
0000-0002-9999-4003
PMID 34708874
ParticipantIDs pubmed_primary_34708874
PublicationCentury 2000
PublicationDate 2022-04-00
PublicationDateYYYYMMDD 2022-04-01
PublicationDate_xml – month: 04
  year: 2022
  text: 2022-04-00
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Journal of clinical pharmacology
PublicationTitleAlternate J Clin Pharmacol
PublicationYear 2022
SSID ssj0016451
Score 2.5759816
SecondaryResourceType review_article
Snippet This article discusses current literature on the use of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in the treatment of posttraumatic...
SourceID pubmed
SourceType Index Database
StartPage 463
SubjectTerms Combined Modality Therapy
Humans
N-Methyl-3,4-methylenedioxyamphetamine - adverse effects
N-Methyl-3,4-methylenedioxyamphetamine - therapeutic use
Psychotherapy
Stress Disorders, Post-Traumatic - drug therapy
Stress Disorders, Post-Traumatic - psychology
Treatment Outcome
Title MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis
URI https://www.ncbi.nlm.nih.gov/pubmed/34708874
Volume 62
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6lVEK9IF4tb80B9UKXxvE-Gm4RUEVFQZWaot6qXe8uhEcSpe6h_CP-JbNer9duqaBcrMhrW9F-n8Yz45lvCHlpc238a4tyJgVl1jE6VEJQyYQd9q3pF8Y3OE8-ivExOzjhJ73er1bV0nmpXxc__9hX8j-o4jnE1XfJ3gDZ5qF4An8jvnhEhPH4TxhP3k1GFDfYQ2VqWxYaqkIZ5rSpIq8q3c7KcqXOg0brUegRieKboUH9KMk6R8F9n6ad2FLRqF5yjTfbdFgukxZ2k61v0jcfZn7-yPeLVymzMytmn-eqGgCOFPy2KFX6UjVuJ7lHZuWN0af0GqlH-3Vr_-sMBga_qfDF1laXDygTYQ5xNMti0KIfa9lYFiziFdsftGS_FssvvgWTt6_BTVz-qEiQM-ntKvv76iUZ7ri0RtYwIPETVn1aqP5cJRjPomxVf7Db_IcNcjvedylsqdyX6V1yp0YKRoFE90jPzu-T7cMA1sUOTFMf3tkObMNhC8YHZNVhGnSYBsg0aJgGCwcdpkFgGkSmvYERJJ5B4Bl4nkGHZw_J8f776dsxrad10CLnOaeZQW9VG2Xzwu31jZYmY9LxnClhOYYh3A2VQ3dwiFG_ziwTmbJoKTIrtdQcPcVNcmu-mNtHBLjRDrdU4gUF0zbf067QGAtoM8gNs_Ix2Qp7eboMkiyncZefXLvylGwk7j0j6w5tgH2ODmWpX1Rg_gakcHzh
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MDMA-Assisted+Psychotherapy+for+Treatment+of+Posttraumatic+Stress+Disorder%3A+A+Systematic+Review+With+Meta-Analysis&rft.jtitle=Journal+of+clinical+pharmacology&rft.au=Smith%2C+Kimberly+W&rft.au=Sicignano%2C+Dakota+J&rft.au=Hernandez%2C+Adrian+V&rft.au=White%2C+C+Michael&rft.date=2022-04-01&rft.eissn=1552-4604&rft.volume=62&rft.issue=4&rft.spage=463&rft_id=info:doi/10.1002%2Fjcph.1995&rft_id=info%3Apmid%2F34708874&rft_id=info%3Apmid%2F34708874&rft.externalDocID=34708874